User:Mr. Ibrahem/Siponimod

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Siponimod
Clinical data
Trade namesMayzent[1]
Other namesBAF-312
AHFS/Drugs.comMonograph
MedlinePlusa619027
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classSphingosine-1-phosphate receptor modulator[3]
Legal status
Legal status
  • AU: S4 (Prescription only)[4]
  • UK: POM (Prescription only)[5]
  • US: ℞-only
  • EU: Rx-only[6]
  • In general: ℞ (Prescription only)
Identifiers
  • 1-({4-[(1E)-1-({[4-Cyclohexyl- 3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid
Chemical and physical data
FormulaC29H35F3N2O3
Molar mass516.605 g·mol−1
3D model (JSmol)
  • CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O
  • InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+
  • Key:KIHYPELVXPAIDH-HNSNBQBZSA-N

Siponimod, sold under the brand name Mayzent, is a medication used to treat multiple sclerosis (MS).[7] Specifically it is used for relapsing forms of MS including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[7] It is taken by mouth.[7]

Common side effects include headache, high blood pressure, and liver problems.[7] Other side effects may include infection, macular edema, arrhythmias, and posterior reversible encephalopathy syndrome.[9] It should not be used in people who are allergic to peanuts or to soya.[3] It works by blocking sphingosine-1-phosphate receptors.[3]

Siponimod was approved for medical use in the United States in 2019 and Europe in 2020.[3][9] At a dose of 2 mg per day, it costs about 8,400 USD per month in the United States as of 2021.[10] In the United Kingdom this amount costs the NHS about £1,800.[11] In the United States it is only available through a specialty pharmacy.[9]

References[edit]

  1. ^ "FDA approves new oral drug to treat multiple sclerosis". U.S. Food and Drug Administration (FDA) (Press release). 26 March 2019. Archived from the original on 27 November 2019. Retrieved 24 November 2019.Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ "Mayzent Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 December 2019. Archived from the original on 5 March 2020. Retrieved 23 August 2020.
  3. ^ a b c d e "Mayzent". Archived from the original on 27 March 2020. Retrieved 12 October 2021.
  4. ^ "Summary for ARTG Entry:310499 Mayzent siponimod 2 mg film-coated tablet blister pack" (PDF). Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.{{cite web}}: CS1 maint: url-status (link)
  5. ^ "Mayzent 2 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 24 April 2020. Archived from the original on 2 March 2021. Retrieved 23 August 2020.
  6. ^ "Mayzent EPAR". European Medicines Agency (EMA). 12 November 2019. Archived from the original on 27 March 2020. Retrieved 3 May 2020.
  7. ^ a b c d e f "Mayzent- siponimod tablet, film coated". DailyMed. 26 March 2019. Archived from the original on 29 August 2021. Retrieved 22 January 2020.
  8. ^ "Siponimod (Mayzent) Use During Pregnancy". Drugs.com. 15 April 2019. Archived from the original on 29 November 2020. Retrieved 22 January 2020.
  9. ^ a b c "Siponimod Monograph for Professionals". Drugs.com. Archived from the original on 25 February 2021. Retrieved 12 October 2021.
  10. ^ "Mayzent Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 February 2021. Retrieved 12 October 2021.
  11. ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 903. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Siponimod&oldid=1219502528"